HomeGlibenclamideGlibenclamide + Pretomanid

Does Glibenclamide Interact with Pretomanid?

Glibenclamide and Pretomanid have a unknown drug interaction according to U.S. FDA drug labeling data. BCRP substrate. In vitro studies suggest pretomanid may inhibit BCRP, potentially increasing glyburide exposure. Clinical impact unknown; monitor for adverse reactions. The mechanism involves potential bcrp transporter inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Glibenclamide Class
Sulfonylurea
Pretomanid Class
Antimycobacterial
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Glibenclamide and Pretomanid occurs because potential bcrp transporter inhibition. Clinically, this means bcrp substrate. in vitro studies suggest pretomanid may inhibit bcrp, potentially increasing glyburide exposure. clinical impact unknown; monitor for adverse reactions.

What To Tell Your Doctor or Pharmacist

If you are taking Glibenclamide and your doctor is considering prescribing Pretomanid (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Glibenclamide+💊 Pretomanid(Pretomanid)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Sulfonylurea
Drug B class
Antimycobacterial
Source
NLP:pretomanid

What this means in plain English

BCRP substrate. In vitro studies suggest pretomanid may inhibit BCRP, potentially increasing glyburide exposure. Clinical impact unknown; monitor for adverse reactions.

What the FDA label says

"Potential BCRP transporter inhibition"

📖 Source: NLP:pretomanid

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Glibenclamide and Pretomanid against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.